Pipeline Programs
CGT Companies Tracked
Manufacturing Facilities
The Europe biotechnology market size stood at USD 465.87 billion in 2025, grew to USD 518.51 billion in 2026, and is forecast to reach USD 1358.99 billion by 2035, expanding at a CAGR of 11.30% from 2026 to 2035.
Day by day, Europe is expanding its biotech and pharma facilities across different countries, with the greater adoption of advanced technologies, like AI, gene editing technologies. Moreover, the rising diversity of chronic illnesses is supporting the continuous investment in R&D, along with a phenomenal EU support. The emergence of leading companies, like Roche, Novartis, and Bayer AG, is leveraging sophisticated bio-services and innovation in targeted therapies. Whereas, Nordics are bolstering the cluster of biotech & research academic institutions for novel solutions in genomics, & DNA sequencing.
The Europe biotechnology market covers biopharmaceuticals, agricultural biotech, industrial biotech, and bio-services across the region. Outsourcing, biotech hubs (Germany, Switzerland, UK, France, Netherlands, Scandinavia), and collaboration between academia and industry are major market drivers. Europe is a global leader in biopharma R&D, cell & gene therapy innovation, and biosimilars adoption, supported by strong regulatory oversight from the European Medicines Agency (EMA) and robust research funding under programs like Horizon Europe. The region’s strengths lie in advanced biologics manufacturing, stem cell research, and synthetic biology, while growing demand for sustainable biofuels, bioplastics, and agri-biotech is diversifying the sector.
Europe’s biotechnology market is influenced by both internal and external factors. Internal factors include research capabilities, availability of skilled scientists, laboratory infrastructure, funding capacity, technology adoption, manufacturing expertise, and collaboration networks. External factors include regulatory policies, healthcare demand, economic conditions, investment trends, demographic changes, and evolving environmental requirements. Rising demand for advanced therapies, sustainable biological solutions, and precision medicine is encouraging biotechnology companies to expand their capabilities. At the same time, complex regulations, high R&D costs, talent shortages, and funding uncertainties can restrict market development. Rapid advancements in artificial intelligence, genomics, gene editing, bioinformatics, and automation are creating new opportunities for innovation. Increasing partnerships between biotechnology firms, pharmaceutical companies, academic institutions, and technology providers are further supporting commercialization and strengthening Europe’s competitive biotechnology landscape.
| Regulatory Body | Initiatives |
| UK Government | Launched a new industrial strategy that comprises a commitment to invest £380m in engineering biology. |
| InvestAI | Securing €200 billion to develop "AI gigafactories" in several sectors, including biotech. |
| Horizon Europe | Invested €7.3 billion 2025 work program for research and innovation allocates substantial funding to areas related to biotechnology. |
The respective market is widely utilizing AI algorithms in various areas of biotechnology, particularly in drug discovery, diagnosis, and personalized treatment. Recently, various companies have presented their approaches, including Cytocast's digital twin patient platform for drug development, Exscientia's AI-assisted drug discovery for Sanofi, and Elixir Health's utilization of AI in fertility treatment by analyzing patient data.
For instance,
The Europe biotechnology market encompasses the development and commercialization of biological products, technologies, and processes used across healthcare, agriculture, industrial applications, and environmental solutions. The market is growing due to increasing investment in life sciences, rising demand for advanced therapies, expanding research activities, and growing adoption of biotechnology across industries, chronic disease burden, supportive innovative initiatives, and expanding biopharmaceutical manufacturing. Trends include personalized medicines, cell and gene therapies, synthetic biology, precision fermentation, and sustained bioprocessing.
Technological advancements such as artificial intelligence, gene-editing platforms, automation, bioinformatics, and product development. Future opportunities are emerging through next-generation therapeutics, engineered biological systems, bio-based manufacturing, and integration of digital technologies with biotechnology. Increasing collaboration between biotechnology companies, research institutions, pharmaceutical organizations, and technology providers is expected to further strengthen the European biotechnology ecosystems.
| Table | Scope |
| Market Size in 2026 | USD 518.51 Billion |
| Projected Market Size in 2035 | USD 1358.99 Billion |
| CAGR (2026 - 2035) | 11.30% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Product/Service, By Technology, By Application, By End User, By Country |
| Top Key Players | Merck KGaA (Germany), Qiagen (Germany/Netherlands), Evotec SE (Germany) , Sanofi (France), Ipsen (France), Servier (France), AstraZeneca (UK), GSK (UK), Oxford Biomedica (UK), Genmab (Denmark), Bavarian Nordic (Denmark), Novo Nordisk (Denmark), Actelion (Switzerland, J&J subsidiary), BioNTech (Germany), CureVac (Germany) |
The biopharmaceuticals segment held 43% revenue share of the market in 2025. The segment is mainly driven by a rise in instances of chronic disease, with a preference for targeted biologics and advancements in gene therapies. In the last few days, a proposed new European biotech act has focused on a holistic approach to regulation and funding, with major investments in R&D by companies, including Sanofi and BioNTech's acceleration into tailored cancer vaccines, and innovative solutions, especially Bayer's cell and gene therapy for Parkinson's research.
Whereas the bioservices segment is anticipated to expand rapidly in the coming era. The presence of a robust research ecosystem, outsourcing R&D, manufacturing, and support functions, is impacting the comprehensive bioservices in Europe. Current milestone steps in bioservices, such as a crucial M&A activity with companies like Genmab acquiring Merus, breakthroughs in gene therapy with UniQure's trial success, and continuous emphasis on soil biodiversity projects like the EU-funded BIOservicES initiative to boost land management and sustainability.
In 2025, the DNA sequencing & genomics segment captured 27% revenue share of the Europe biotechnology market. The segment covers the increasing demand for personalized medicine, technological advances, and escalated government funding for genomic research. Nowadays, Europe is focusing on large-scale, collaborative initiatives like the Genome of Europe (GoE) project, comprising the 1+Million Genomes initiative, over 30 countries are contributing to whole-genome sequencing and data sharing via the secure Genomic Data Infrastructure (GDI) project.
However, the CRISPR & gene editing segment is predicted to expand at a rapid CAGR. Involvement of a strong biotech & pharmaceutical hub, and programs like Horizon Europe with significant funding for genome editing research, supporting both public and private sectors to adopt CRISPR technology. Ongoing research activities, such as a huge contribution of the European Research Council (ERC) in the exploration of CRISPR for applications in cancer gene regulation, neurodegenerative diseases, and other areas, are also propelling the overall market growth.
In 2025, the healthcare/medical biotechnology segment held the biggest revenue share of 47% of the market. The segment is eventually fueled by the growing demand for customized treatments based on individual genetic profiles by European consumers and healthcare systems. Alongside, Europe is fostering the transformation of new solutions, such as cardio-immunology and microbiome therapies, and the expansion of antibody-based treatments for autoimmune diseases. The medical sector is imposing advances in gene therapies (like for Huntington's disease) and mRNA vaccines.
Moreover, the industrial biotechnology segment will register the fastest growth during 2025-2034. The arising demand for sustainability approaches, innovation, and supportive government policies is encouraging industrial biotechnology progress. Furthermore, Europe is putting efforts into developments in molecular and computational tools that allow the design of specific traits in microorganisms and plants, resulting in robust and targeted applications. Ongoing manipulation of materials at the nanoscale is bolstering the revolution of drug delivery systems and sophisticated biosensors.
In the Europe biotechnology market, the pharma & biotech companies segment registered dominance with 45% revenue share in 2025. Consistent healthcare expenses are assisting innovative technological advancements in areas like AI and CRISPR, and progress in research areas is fostering the various pharma & biotech companies in Europe. The latest step, like the French startup Bioptimus, is seeking the use of generative AI for drug discovery. Novo Nordisk is involved in new diabetes and obesity treatments, while companies like Polygon Therapeutics are pursuing new immunotherapies for cardiovascular conditions.
Whereas the CROs & CDMOs segment is predicted to expand fastest in the coming era. The widespread adoption of advanced technologies, like AI & big data, ongoing strategic trend of outsourcing to enhance accessibility of expertise, expenditure, and effectiveness. These facilities are experiencing regulatory and societal pressures, with a raised focus on green chemistry, energy-efficient equipment, and zero-waste manufacturing to optimize sustainability.
Why did Germany Dominate the Market in 2025?
By capturing 22% revenue share of the Europe biotechnology market, Germany registered dominance in 2024. A prominent catalyst is the prioritizing of biotechnology by both the German government and the EU, with heavy investment in infrastructure, funding innovation, and encouraging biotechnology research and development.
For instance,
UK Biotechnology Surges Through Research Excellence and Innovation
The UK biotechnology market is growing significantly due to its strong life sciences ecosystem, world-class research institutions, skilled scientific workforce, and increasing investment in biotechnology innovation. Close collaboration between universities, biotechnology companies, pharmaceutical firms, and research organizations supports faster development of advanced products. Growing adoption of artificial intelligence, genomics, cell and gene therapies, and synthetic biology is further strengthening the market. Increasing demand for innovative healthcare solutions creates additional opportunities for sustained growth.
The biotechnology market is projected to grow from USD 1,744.83 billion in 2025 to USD 5,036.46 billion by 2034, reflecting a CAGR of 12.5% over the period, driven by innovation and technological advancements in the industry.
In the future, the Nordics will grow at a rapid CAGR in the Europe biotechnology market. This expansion will be fueled by the rigorous biotech clusters, such as Medicon Valley, spanning Copenhagen (Denmark) and southern Sweden, which act as magnets for R&D. Additionally, the Nordics possess world-class universities and research institutions, especially the Karolinska Institute in Sweden and the Technical University of Denmark. These institutions are promoting alliance among academia and industry, leading to a robust pipeline of talent and spin-off companies.
For this market,
Strengths
Weaknesses
Opportunities
Threats
By Product/Service
By Technology
By Application
By End User
By Country
Principal Consultant
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Learn more about Payal Rabde
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
